Girot R, Triadou P, Bories D, Jeannel F, Thevenin M, Rymer J C
Nouv Rev Fr Hematol (1978). 1982;24(5):281-7.
A total of 21 patients with thalassaemia major between 2 and 20-years-old were on a "hypertransfusion" regimen for 1 to 14 year periods. The use of the transfusion quotient (TQ) allowed a precise survey of the blood requirement. In all splenectomized patients the TQ was between 1 and 2; TQ increased and was always greater than 2 when patients became hypersplenic. Of the 21 regularly transfused patients, 12 had iron chelation therapy by continuous subcutaneous desferrioxamine (DF) injection (1 g over 8 to 12 h at home, nightly). The iron balance was negative for 7 patients, equilibrated for 1 and positive for 4 patients. All patients receiving more than injections of DF weekly had a negative balance; the variation of the serum ferritin level correlated with the iron balance (r = 0,77; P less than 0,01). The beneficial effects of the treatment were improvement in social and professional activity, in growth and puberty development and attenuation of the skull and face dysmorphia. Monitoring ferritin is a simple way to estimating the effects of chelation on iron overload.
共有21例2至20岁的重型地中海贫血患者接受了1至14年的“强化输血”治疗方案。通过输血商数(TQ)可以精确地评估血液需求量。所有脾切除患者的TQ在1至2之间;当患者出现脾功能亢进时,TQ升高且始终大于2。在21例定期输血的患者中,12例通过皮下持续注射去铁胺(DF)进行铁螯合治疗(在家每晚8至12小时注射1克)。7例患者铁平衡为负,1例平衡,4例为正。所有每周接受DF注射超过规定剂量的患者铁平衡均为负;血清铁蛋白水平的变化与铁平衡相关(r = 0.77;P < 0.01)。治疗的有益效果包括社交和职业活动改善、生长和青春期发育改善以及头颅和面部畸形减轻。监测铁蛋白是评估螯合治疗对铁过载影响的一种简单方法。